title: Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.
abstract: Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non-clear-cell RCC, but data on outcomes in this setting are limited.
  
  
  
  We conducted a retrospective data analysis of records of consecutive metastatic non-clear-cell RCC patients who received pazopanib in front-line and salvage settings between November 2009 and November 2012. Tumor response rate was assessed by a blinded radiologist using Response Evaluation Criteria in Solid Tumors version 1.1. PFS and overall survival (OS) times were estimated using Kaplan-Meier methods.
  
  
  
  Twenty-nine patients were identified with non-clear-cell metastatic RCC, 9 received pazopanib in the front-line setting, 20 in the salvage setting after progression of disease with other targeted therapies. Seven patients (24%) had papillary RCC, 4 (14%) had chromophobe, 5 (17%) had unclassified histopathology, and 13 (45%) had other subtypes including collecting duct, translocation Xp11.2, and various subtypes with sarcomatoid differentiation. All patients discontinued pazopanib before analysis. Median PFS was 8.1 months (95% CI, 5.7-NA [not available]) in the front-line group, and 4 months (95% CI, 2.1-9.9) in the salvage group. Median OS was 31 months (95% CI, 9.2-NA) in the front-line group, and 13.6 months (95% CI, 6.4-NA) in the salvage group.
  
  
  
  Pazopanib showed efficacy in patients with metastatic non-clear-cell RCC in the front-line and salvage settings. Toxicity was mild to moderate and manageable. Further studies are needed to evaluate pazopanib's role in non-clear-cell RCC in terms of efficacy and safety.
authors: Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: mamatrana@ochsner.org.
authors: Marc R
authors: MR
authors: Matrana
authors: Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Ali
authors: A
authors: Baiomy
authors: Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Matthew
authors: M
authors: Campbell
authors: Ochsner Cancer Institute, Ochsner Clinic Foundation, New Orleans, LA.
authors: Suhail
authors: S
authors: Alamri
authors: Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Aditya
authors: A
authors: Shetty
authors: Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Purnima
authors: P
authors: Teegavarapu
authors: Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Sarathi
authors: S
authors: Kalra
authors: Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Lianchun
authors: L
authors: Xiao
authors: Clinical Pharmacy Programs, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Bradley
authors: B
authors: Atkinson
authors: Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Paul
authors: P
authors: Corn
authors: Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Eric
authors: E
authors: Jonasch
authors: Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Khaled M
authors: KM
authors: Elsayes
authors: Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Nizar M
authors: NM
authors: Tannir
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011743:Pyrimidines / Q000008:administration & dosage* / Q000627:therapeutic use; D012189:Retrospective Studies; D013449:Sulfonamides / Q000008:administration & dosage* / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib
keywords: Angiogenesis; Kidney cancer; Late relapse; Targeted therapy; Tyrosine-kinase inhibitor; mTOR inhibitor